Medications

Patients and clinicians considering sequencing of advanced UC therapies may care because this study reports differences in how long patients stayed on second-line treatment depending on the order of anti-TNF agents and...

This small case series suggests upadacitinib may induce and maintain steroid-free remission in some UC patients after tofacitinib failure, a potential option for people with refractory disease.

This review highlights a potential new class of IBD drugs (RIPK1 inhibitors) that target inflammatory and cell-death pathways implicated in epithelial injury. For people with IBD, it signals an area of active research...

GLP-1 receptor agonists — drugs commonly used to treat obesity and metabolic disease — may help patients with IBD by reducing visceral fat and improving cardiometabolic health.

Identifies candidate drug‑level and immune biomarker cut‑points linked with endoscopic healing in pediatric Crohn's disease, which could help guide dosing or treatment changes if validated.

The study evaluates how well first-line 5-ASA therapy achieves modern treatment targets (endoscopic, histologic, and biomarker remission) in real-world UC patients who are clinically in remission. Patients and clinicians...

Biologics and newer small molecules have markedly changed IBD care and outcomes for many patients, but their population-level impact depends on access, cost, and how they are used. Understanding this helps patients and...

This study addresses whether being on biologic or small‑molecule IBD drugs before colorectal surgery affects short‑term postoperative complications — a practical concern for patients and clinicians planning surgery.

If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.

Short-term mental health problems (depression, anxiety, adjustment disorders) appear more common after ostomy creation than after nonostomy IBD surgery among biologic-treated adults. Awareness may help patients and...

The study suggests a specific stromal and MAPK/EGFR signalling programme linked to prior anti‑TNF failure in ulcerative colitis, which could help explain why some patients are less responsive to later therapies and point...

Patients and clinicians are interested in whether combining two targeted biologic therapies can induce stronger endoscopic healing for people with difficult-to-treat Crohn's disease, and whether benefit can be maintained...

The study tests whether combining a standardized coping-skills program with biologic therapy improves emotional well-being and clinical/endoscopic outcomes in people with early Crohn's disease—addressing common...

A new pediatric Phase 3 trial of filgotinib could broaden approved treatment choices for children and teens with moderate-to-severe ulcerative colitis, especially for those who have not responded to or cannot tolerate...

A new oral investigational drug (HRS-7085) is entering early human testing for moderate-to-severe ulcerative colitis. People with UC who have not benefited from approved therapies may be interested in trial options and...

Researchers are testing whether short-term dual therapy with vedolizumab plus tofacitinib can induce remission in people with moderate–severe UC who have failed prior TNF blockers. If effective and safe, this approach...

The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative...

Surgical care for Crohn’s disease affects many patients with complicated disease. The study suggests modern practice increasingly uses laparoscopic approaches and sees fewer emergency surgeries and stomas, which can mean...

Targeted release of mesalamine to the colon could increase local drug levels and reduce upper-GI exposure and systemic side effects. New delivery platforms may improve effectiveness for ulcerative colitis without...

The study suggests anti-TNF failure in Crohn's may be driven by pre-existing cytokine interaction networks and loss of regulatory feedback, which could help explain why some patients don't respond to TNF-blocking...

Based on the title and source metadata, this appears to be a regulatory update related to Mirikizumab, IL-23 inhibitor, and Medications. The original article is from DailyMed.

Shattuck Labs plans to advance a DR3-targeting bispecific antibody (SL-325) into a Phase 2b trial for Crohn's disease, which is relevant to people watching new investigational biologics for IBD. The report is a...

If PALI-2108 proves safe and effective in Phase 2 trials, it could add a new oral treatment option for people with ulcerative colitis and Crohn’s disease. Early Phase 1 signals and a funded Phase 2 program mean the...

This case suggests ustekinumab — a commonly used biologic for Crohn’s disease — might rarely be associated with kidney injury (FSGS). Patients and clinicians should be aware of new or worsening edema, proteinuria, or...

Growth and new approvals for Skyrizi and Rinvoq may increase treatment options and influence which drugs gastroenterologists prescribe for Crohn’s disease and ulcerative colitis. Changes in approvals, dosing options, and...

Cure8 indexed source-provided abstract text from The Journal of Dermatology, but this record did not meet the threshold for a full Cure8 brief. It is tagged for Crohn's disease, Inflammatory bowel disease, and...

Long-term extension trials help show whether a drug’s benefits and safety persist over time. For people with Crohn’s disease, this study focuses on maintaining endoscopic improvement and clinical remission with...

This news matters because SL-325 targets the TL1A/DR3 pathway, a novel immune target being tested for Crohn’s disease and UC; early Phase 1 data suggest a tolerable profile and prolonged target blockade that could affect...

The trial tests two low-cost adjuncts — a Lactobacillus probiotic and a multi–trace-element supplement — added to biologic-based standard care to see if they help maintain remission in ulcerative colitis. If effective,...

Early clinical data suggest SL-325 engages its target (TL1A) with a favorable safety signal, and a Phase 2b trial in Crohn’s disease is planned — meaning this could become a new treatment option in the future if later...

Cure8 could only read part of this source from PubMed Central, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Natalizumab, and Biosimilars.

If you or a loved one follow emerging IBD treatments, this update signals a new PALI-2108 program moving into Phase 2 for ulcerative colitis and planned Phase 2 testing in Crohn’s disease, plus a company focus on...

Cure8 found this source from Intestinal research, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Risankizumab. Open the original article for the full...

The study presents a gut-targeted bispecific that aims to both block gut-homing/inflammatory signals and activate epithelial repair — a combined approach that could reduce systemic immunosuppression while promoting...

This review pools available human and animal studies on sodium butyrate for ulcerative colitis and highlights promising signals—especially for oral microencapsulated formulations—while noting that clinical evidence is...

This review organizes and grades causal evidence linking individual gut bacteria, their metabolites, and host pathways in IBD—helping researchers and clinicians see which microbe–metabolite mechanisms are best supported...

Patients with ulcerative colitis who cannot tolerate 5-ASA need alternative maintenance options. This study suggests azathioprine showed comparable continuation, safety, and endoscopic outcomes whether or not patients...

For people with UC and CMV colitis, whether to keep or stop immunosuppressive drugs during antiviral treatment may affect how quickly CMV clears from colon tissue and short-term adverse events.

Keeping IBD well controlled before and during pregnancy lowers the risk of adverse outcomes for both parent and baby; understanding which medications are safe and which should be stopped is crucial for family planning.

Researchers are exploring a way to deliver biologic drugs directly in the gut using engineered B cells that become long-lived plasma cells. If successful, this could allow sustained, localized anti-inflammatory protein...

Researchers are exploring a new way to block colon-homing T cells using a GPR15-targeting peptide; if successful, this could lead to a novel mechanism for treating IBD patients who don’t respond to current therapies.

A Cochrane network meta-analysis compares many biologic medicines used for Crohn’s disease, which can help patients and clinicians understand how different drugs and drug classes stack up for inducing and keeping...

If you have IBD and take biologic therapy plus other medicines, inflammation and anti-cytokine treatment may change how your other drugs are metabolized. This review discusses ways researchers are trying to predict and...

Predicting who will respond to anti-TNF drugs could help avoid ineffective treatments, reduce delays to effective therapy, and personalize care for children with Crohn's disease.

Anti‑TNF drugs are a mainstay of IBD treatment. Understanding that they act through several immune mechanisms (not only neutralizing soluble TNF‑α) helps explain differences in effectiveness and informs conversations...

This pooled analysis focuses on children with IBD and reports that ustekinumab was associated with substantial clinical and steroid-free remission rates and a low incidence of serious adverse events—information that may...

The review connects microbiome-targeted therapies (diet, probiotics, FMT, antibiotics, and newer approaches) to mechanisms relevant to IBD and systemic health, highlighting why these strategies are of interest to...

If validated, metabolite patterns could help predict which children will reach remission on vedolizumab, potentially guiding treatment choices and avoiding ineffective therapy.